Halozyme Therapeutics | HALO - Market Capitalization


Halozyme Therapeutics reported $8.56B in Market Capitalization this May of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 3.57B 221M May/2026
Agios Pharmaceuticals USD 2.01B 423M Mar/2026
Alnylam Pharmaceuticals USD 44.15B 8.39B Mar/2026
Amarin USD 290M 51M Dec/2025
Amgen USD 189.89B 13.64B Mar/2026
Baxter International USD 8.67B 1.15B Mar/2026
Cara Therapeutics USD 366M 338M Sep/2025
Cytokinetics USD 9.16B 975M May/2026
DBV Technologies USD 274M 17M Sep/2025
Eli Lilly USD 869.02B 146.97B Mar/2026
Esperion Therapeutics USD 885M 351M Dec/2025
Halozyme Therapeutics USD 8.56B 905M May/2026
Ionis Pharmaceuticals USD 12.46B 356M Mar/2026
MannKind USD 965M 208M May/2026
Nektar Therapeutics USD 15.62B 14.76B May/2026
Pfizer USD 147.4B 6.42B May/2026
United Therapeutics USD 28.08B 2.9B May/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024